Synthetic peptide issued from Hap1/LipL32 for new early serodiagnosis of human leptospirosis
Copyright 2009 Elsevier Ltd. All rights reserved..
Leptospirosis is a worldwide zoonosis. Today, serological diagnosis is generally assessed by MAT. We performed ELISA with a synthetic peptide derived from Hap1/lipL32 which is a protein expressed only by pathogenic Leptospira. Repeatability and thresholds were defined with 85 controls sera and 119 hospitalized leptospirosis. The PP-ELISA repeatability and IgM/IgG cut-off values were based on control sera. For these cut-off values, we observed the IgM-PP-ELISA specificity of 89%, whereas it was 100% for the IgG. Then, we compared PP-ELISA and standard MAT results for leptospirosis patients. The concordance rate for IgM-PP-ELISA and MAT was low (43%), whereas it was 85% for IgG-PP-ELISA and MAT. During the first 5 days after hospitalization, PP-ELISA gave positive results in 13 out of 16 patients (81%) whereas 8 out of 14 patients (57%) were positive to MAT. ELISA using Hap1/lipL 32-derived synthetic peptide PP is an earlier serological diagnosis of human leptospirosis than MAT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Comparative immunology, microbiology and infectious diseases - 33(2010), 5 vom: 10. Sept., Seite 375-87 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aviat, F [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.12.2010 Date Revised 11.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cimid.2009.01.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM187276250 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM187276250 | ||
| 003 | DE-627 | ||
| 005 | 20231223175725.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cimid.2009.01.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0624.xml |
| 035 | |a (DE-627)NLM187276250 | ||
| 035 | |a (NLM)19307019 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aviat, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthetic peptide issued from Hap1/LipL32 for new early serodiagnosis of human leptospirosis |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2010 | ||
| 500 | |a Date Revised 11.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2009 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Leptospirosis is a worldwide zoonosis. Today, serological diagnosis is generally assessed by MAT. We performed ELISA with a synthetic peptide derived from Hap1/lipL32 which is a protein expressed only by pathogenic Leptospira. Repeatability and thresholds were defined with 85 controls sera and 119 hospitalized leptospirosis. The PP-ELISA repeatability and IgM/IgG cut-off values were based on control sera. For these cut-off values, we observed the IgM-PP-ELISA specificity of 89%, whereas it was 100% for the IgG. Then, we compared PP-ELISA and standard MAT results for leptospirosis patients. The concordance rate for IgM-PP-ELISA and MAT was low (43%), whereas it was 85% for IgG-PP-ELISA and MAT. During the first 5 days after hospitalization, PP-ELISA gave positive results in 13 out of 16 patients (81%) whereas 8 out of 14 patients (57%) were positive to MAT. ELISA using Hap1/lipL 32-derived synthetic peptide PP is an earlier serological diagnosis of human leptospirosis than MAT | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Bacterial |2 NLM | |
| 650 | 7 | |a Antigens, Bacterial |2 NLM | |
| 650 | 7 | |a Bacterial Outer Membrane Proteins |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a LipL32 protein, Leptospira |2 NLM | |
| 650 | 7 | |a Lipoproteins |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 700 | 1 | |a Rochereau-Roulet, S |e verfasserin |4 aut | |
| 700 | 1 | |a Branger, C |e verfasserin |4 aut | |
| 700 | 1 | |a Estavoyer, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Chatrenet, B |e verfasserin |4 aut | |
| 700 | 1 | |a Orsonneau, J L |e verfasserin |4 aut | |
| 700 | 1 | |a Thorin, C |e verfasserin |4 aut | |
| 700 | 1 | |a Andre-Fontaine, G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Comparative immunology, microbiology and infectious diseases |d 1993 |g 33(2010), 5 vom: 10. Sept., Seite 375-87 |w (DE-627)NLM00042952X |x 1878-1667 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2010 |g number:5 |g day:10 |g month:09 |g pages:375-87 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cimid.2009.01.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2010 |e 5 |b 10 |c 09 |h 375-87 | ||